Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.

The synergistic effects of recombinant human tissue-type plasminogen activator (rt-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on coronary arterial thrombolysis were investigated in open-chest dogs with thrombosis of the left anterior descending coronary artery and a superimposed high-grade stenosis. A 90% stenosis was generated by external constriction, reducing blood flow to 40 +/- 10% of baseline. Localized thrombosis was produced by endothelial cell injury and instillation of thrombin and fresh blood. Intravenous infusion for 60 minutes of either 30 micrograms/kg/min rt-PA alone or 10 micrograms/kg/min scu-PA alone consistently produced coronary artery recanalization (six of eight dogs and five of five dogs, respectively) but was almost always associated with reocclusion during or shortly after the end of the infusion (four of six dogs and five of five dogs, respectively). Infusion of either 15 micrograms/kg/min rt-PA or 5 micrograms/kg/min scu-PA for 60 minutes did not cause coronary artery recanalization (none of four dogs in each group). Combined infusion of 7.5 micrograms/kg/min rt-PA and 2.5 micrograms/kg/min scu-PA for 60 minutes (one fourth of the minimum thrombolytic dose of each agent) induced coronary artery recanalization (six of six dogs) but was also associated with early reocclusion (six of six dogs). Combined infusion of 3.75 micrograms/kg/min rt-PA and 1.25 micrograms/kg/min scu-PA for 60 minutes did not consistently cause recanalization (one of four dogs). Combined infusion of 15 micrograms/kg/min rt-PA and 5 micrograms/kg/min scu-PA for 60 minutes caused recanalization in all of six dogs but was associated with reocclusion in all six.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  H. Gold,et al.  Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. , 1988, Thrombosis research.

[2]  H. Gold,et al.  Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. , 1988, The Journal of clinical investigation.

[3]  D. Collen Synergism of thrombolytic agents: investigational procedures and clinical potential. , 1988, Circulation.

[4]  H. Gold,et al.  Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. , 1988, Circulation.

[5]  A. Ross,et al.  Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy. , 1987, Circulation.

[6]  G. Steinbeck,et al.  Frequency analysis of the surface electrocardiogram for recognition of acute rejection after orthotopic cardiac transplantation in man. , 1987, Circulation.

[7]  B. Sobel,et al.  Tissue Plasminogen Activator in Thrombolytic Therapy , 1987 .

[8]  I. Jang,et al.  Thrombolysis with Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator (rscu-PA): Dose–Response in Dogs with Coronary Artery Thrombosis , 1987, Journal of cardiovascular pharmacology.

[9]  V. Darras,et al.  Measurement of Urokinase-Type Plasminogen Activator (u-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies , 1986, Thrombosis and Haemostasis.

[10]  F. Werf,et al.  Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. , 1986, American heart journal.

[11]  F. Van de Werf,et al.  Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. , 1986, Circulation.

[12]  M. Verstraete,et al.  Synergism of thrombolytic agents in vivo. , 1986, Circulation.

[13]  H. Lijnen,et al.  Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. , 1986, Circulation.

[14]  I. Palacios,et al.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.

[15]  J. J. Spadaro,et al.  Coronary thrombolysis with recombinant human tissue-type plasminogen activator. , 1984, Circulation.

[16]  M C Berenbaum,et al.  Synergy, additivism and antagonism in immunosuppression. A critical review. , 1977, Clinical and experimental immunology.

[17]  M. Verstraete,et al.  A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). , 1963, Clinica chimica acta; international journal of clinical chemistry.

[18]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[19]  D. Ph.DCollenM. Report of the Meeting of the Subcommittee on Fibrinolysis, San Diego, CA, USA, July 13, 1985 , 1985 .